Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07207681 | Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06260774 | Study of TTX-MC138 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 16 | TransCode TherapeuticsINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03993873 | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET(SHIELD-1) | active not recruiting | Phase 1 | 95 | Turning Point Therapeutics, Inc.INDUSTRY | 5 | Oct 1, 2025 | clinicaltrials |
| NCT06126666 | A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 96 | ABL Bio, Inc.INDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06933524 | Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors(ATB-320-001A) | not yet recruiting | Phase 1 | 24 | AutotelicbioINDUSTRY | 0 | Oct 1, 2025 | clinicaltrials |
| NCT07196579 | Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04606472 | A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05385692 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors | active not recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05803018 | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies | recruiting | Phase 1 / Phase 2 | 38 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06241898 | A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 300 | Bliss Biopharmaceutical (Hangzhou) Co., LtdINDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT03191682 | A First-in-Human Study of PRL3-ZUMAB | active not recruiting | Phase 1 | 38 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05163028 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | active not recruiting | Phase 1 | 42 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05485974 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | active not recruiting | Phase 1 | 44 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05841563 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | recruiting | Phase 1 | 125 | PharmaMarINDUSTRY | 3 | Sep 24, 2025 | clinicaltrials |
| NCT05941507 | A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | LigaChem Biosciences, Inc.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT06212076 | Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients | recruiting | Phase 1 / Phase 2 | 60 | Nanjing Immunophage Biotech Co., LtdINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | recruiting | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06520488 | A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 118 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT06469008 | A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06475131 | A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06493864 | A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06500052 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06985355 | A Study of MHB046C Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05807035 | Autologous Tumour Vaccine Trial | recruiting | Phase 1 | 30 | Vaxine Pty LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04064359 | Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | recruiting | Phase 1 | 200 | Oxford BioTherapeutics LtdINDUSTRY | 5 | Sep 16, 2025 | clinicaltrials |
| NCT05055609 | Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors | recruiting | Phase 1 | 94 | TretheraINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06868199 | A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 87 | LaNova Medicines LimitedINDUSTRY | 2 | Sep 12, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07170787 | A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 104 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04632108 | A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 199 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05357651 | A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） | recruiting | Phase 1 | 100 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06468358 | A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors(TRIGGERCD8) | recruiting | Phase 1 / Phase 2 | 194 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06187402 | A Study of LM-24C5 For Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | LaNova Medicines LimitedINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06783569 | A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors | recruiting | Phase 1 | 94 | JiaRay GroupINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07158918 | ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | ABL Bio, Inc.INDUSTRY | 3 | Sep 8, 2025 | clinicaltrials |
| NCT05932862 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 429 | ExelixisINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06209580 | AMT-253 in Patients With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 96 | Multitude Therapeutics Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07156253 | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07157956 | CVL006 Combination Therapy in Advanced Solid Tumors(CVL006-T1002) | not yet recruiting | Phase 1 / Phase 2 | 318 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06873659 | SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 96 | Qurgen Inc.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07067567 | A Study of AK146D1 for Injection in Advanced Solid Tumors | recruiting | Phase 1 | 200 | AkesoINDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT04685226 | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 310 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07142837 | Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 153 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05835609 | PM534 Administered Intravenously to Patients With Advanced Solid Tumors | recruiting | Phase 1 | 30 | PharmaMarINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 6, 2025source: clinicaltrials